CD45 Antibody (T29/33): sc-18901

CD45 Antibody (T29/33) is a mouse monoclonal IgG1 kappa light chain antibody specifically designed to target CD45, also known as Protein Tyrosine Phosphatase Receptor Type C (PTPRC). CD45 is a transmembrane glycoprotein that is universally expressed on all nucleated hematopoietic cells, making it a critical marker for identifying and studying various immune cell populations. Located on the cell surface, CD45 plays an essential role in modulating signal transduction pathways by regulating tyrosine phosphorylation, which is pivotal for T and B cell receptor signaling and overall immune cell activation. This strategic cellular positioning allows CD45 to interact directly with key signaling molecules, thereby influencing immune responses and maintaining cellular communication within the immune system. CD45 monoclonal antibody (T29/33) is raised against the human CCRF-CEM cell line and exhibits reactivity in human samples across multiple applications, including western blotting (WB), immunoprecipitation (IP), Proximity Ligation Assay (PAR), and flow cytometry (FCM). Anti-CD45 antibody (T29/33) recognizes specific epitopes that arise from the alternative splicing of CD45, enabling the differentiation of its various isoforms such as CD45RA, CD45RB, CD45RC, and CD45RO. These isoforms are differentially expressed among distinct immune cell subsets, providing valuable insights into immune cell differentiation and function. By targeting CD45, anti-CD45 antibody (T29/33) facilitates comprehensive analysis and characterization of immune cells, supporting both research endeavors and diagnostic applications in immunology and related fields.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD45 Antibody (T29/33) References:

1. CD45-associated protein is not essential for the regulation of antigen receptor-mediated signal transduction.  |  Kung, C., et al. 1999. Eur J Immunol. 29: 3951-5. PMID: 10602003
2. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma.  |  Ishikawa, H., et al. 2000. Leuk Lymphoma. 39: 51-5. PMID: 10975383
3. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans.  |  Nguyen, JT., et al. 2001. J Immunol. 167: 5697-707. PMID: 11698442
4. CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling.  |  Irles, C., et al. 2003. Nat Immunol. 4: 189-97. PMID: 12496963
5. CD45 regulates apoptosis in peripheral T lymphocytes.  |  Liu, Z., et al. 2006. Int Immunol. 18: 959-66. PMID: 16621865
6. CD45 is required for type I IFN production by dendritic cells.  |  Montoya, M., et al. 2006. Eur J Immunol. 36: 2150-8. PMID: 16856204
7. CD45-Csk phosphatase-kinase titration uncouples basal and inducible T cell receptor signaling during thymic development.  |  Zikherman, J., et al. 2010. Immunity. 32: 342-54. PMID: 20346773
8. Differentiation of CD45‑/CD31+ lung side population cells into endothelial and smooth muscle cells in vitro.  |  Xu, Y., et al. 2019. Int J Mol Med. 43: 1128-1138. PMID: 30628669
9. Engagement of CD45 alters early signaling events in human T cells co-stimulated through TCR + CD28.  |  Bhatta, A., et al. 2020. Cell Immunol. 353: 104130. PMID: 32446033
10. Regulation of CD71+TER119+ erythroid progenitor cells by CD45.  |  Shim, YA., et al. 2020. Exp Hematol. 86: 53-66.e1. PMID: 32450207

The preferred CD45 antibody is CD45 Antibody (35-Z6): sc-1178.